Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

21 Dec 2022

2022 End of Year Review: Cybin

The end of the year is a convenient time to look back on the psychedelic medicine space and take stock on the progress of both the industry and individual companies....

By Microdose NewsDesk

Industry

19 Dec 2022

Atai Initiates Phase 2b Trial of RL-007 for Schizophrenia

Atai's new phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)....

By Microdose NewsDesk

Law & Politics

19 Dec 2022

California Introduces New Bill to Decriminalize Psychedelics

California is once trying to decriminalize psychedelics, as Sen....

By Microdose NewsDesk

Industry

15 Dec 2022

PharmaTher Receives FDA Orphan Drug Designation for Ketamine

The U.S. Food and Drug Administration (FDA) has granted PharmaTher orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Don’t Miss

12 Dec 2022

News You Might Have Missed: Dec 12th 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

8 Dec 2022

Good Results for COMP360 Psilocybin in Bipolar Disorder Study

Positive study results of COMP360 psilocybin therapy in type II bipolar disorder and analysis of the phase 2b trial of COMP360 psilocybin therapy in treatment-resistant depression....

By Microdose NewsDesk

Industry

6 Dec 2022

Enthea Announces Nationwide Rollout: Psychedelic Therapy as Workplace Benefit

Enthea Announces Nationwide Rollout to Offer Psychedelic Therapy as a Workplace Benefit, Set to Launch into 40 U....

By Microdose NewsDesk

Don’t Miss

5 Dec 2022

News You Might Have Missed: Dec 5th 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Finance

2 Dec 2022

Numinus Wellness Reports Q4 2022 and Annual Results

Numinus Wellness has released its Q4 2022 and Annual Results...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.